IFG Advisory LLC Sells 43,338 Shares of Pfizer Inc. (NYSE:PFE)

IFG Advisory LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 51.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,188 shares of the biopharmaceutical company’s stock after selling 43,338 shares during the quarter. IFG Advisory LLC’s holdings in Pfizer were worth $1,186,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Worth Asset Management LLC bought a new position in shares of Pfizer during the first quarter valued at about $29,000. Briaud Financial Planning Inc purchased a new position in shares of Pfizer in the 3rd quarter worth approximately $30,000. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer during the third quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PFE. Truist Financial lowered their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. UBS Group lowered their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Friday, March 1st. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Trading Up 0.7 %

NYSE:PFE opened at $27.77 on Thursday. The company has a 50-day moving average price of $27.47 and a 200-day moving average price of $29.47. The stock has a market cap of $157.25 billion, a price-to-earnings ratio of 77.14, a P/E/G ratio of 1.24 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the previous year, the firm posted $1.14 EPS. The business’s revenue was down 41.3% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.22 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.